Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Corá-Locatelli
G
G
Greenberg
B D
BD
Martin
J D
JD
Murphy
D L
DL
D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D005473:Fluoxetine / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000139:chemically induced* / Q000188:drug therapy; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005473:Fluoxetine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin